Free Trial
NASDAQ:FGEN

FibroGen (FGEN) Stock Price, News & Analysis

$1.22
+0.02 (+1.67%)
(As of 02:50 PM ET)
Today's Range
$1.18
$1.27
50-Day Range
$0.98
$2.64
52-Week Range
$0.33
$19.47
Volume
1.05 million shs
Average Volume
2.61 million shs
Market Capitalization
$121.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

FibroGen MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.75 Rating Score
Upside/​Downside
1,257.9% Upside
$17.00 Price Target
Short Interest
Bearish
6.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$95,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.05) to ($0.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.51 out of 5 stars

Medical Sector

190th out of 918 stocks

Pharmaceutical Preparations Industry

76th out of 418 stocks

FGEN stock logo

About FibroGen Stock (NASDAQ:FGEN)

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FGEN Stock Price History

FGEN Stock News Headlines

Goldman Sachs Remains a Sell on FibroGen (FGEN)
Here's what Wall Street expects from FibroGen's earnings
FibroGen Q1 2024 Earnings Preview
FibroGen (FGEN) Gets a Sell from Goldman Sachs
FibroGen Appoints Deyaa Adib As CMO
See More Headlines
Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
5/21/2024
Next Earnings (Estimated)
8/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FGEN
Employees
486
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$32.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+1,299.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

Net Income
$-284,230,000.00
Net Margins
-143.57%
Pretax Margin
-145.04%

Debt

Sales & Book Value

Annual Sales
$147.75 million
Book Value
($1.87) per share

Miscellaneous

Free Float
97,504,000
Market Cap
$120.86 million
Optionable
Optionable
Beta
0.88
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Thane WettigMr. Thane Wettig (Age 59)
    CEO & Director
    Comp: $941.79k
  • Mr. Juan Graham (Age 47)
    Senior VP & CFO
    Comp: $892.49k
  • Ms. Christine L. Chung (Age 56)
    Senior Vice President of China Operations
    Comp: $915.36k
  • Dr. Barry A. Berkowitz Ph.D.
    Founder
  • Dr. John J. Hunter Ph.D. (Age 61)
    Chief Scientific Officer
  • David DeLucia
    Vice President of Corporate FP&A and Investor Relations
  • Mr. Michael D. Lowenstein J.D.
    Ph.D., Chief Legal Officer
  • Ms. Tricia Stewart
    Chief People Officer
  • Mr. Kirk A. Christoffersen MBA (Age 55)
    Chief Business Officer
  • Dr. Rahul Rajan Kaushik Ph.D.
    Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing

FGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell FibroGen stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" FGEN shares.
View FGEN analyst ratings
or view top-rated stocks.

What is FibroGen's stock price target for 2024?

4 brokers have issued 12-month price objectives for FibroGen's stock. Their FGEN share price targets range from $2.00 to $32.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 1,257.9% from the stock's current price.
View analysts price targets for FGEN
or view top-rated stocks among Wall Street analysts.

How have FGEN shares performed in 2024?

FibroGen's stock was trading at $0.8863 at the start of the year. Since then, FGEN stock has increased by 41.3% and is now trading at $1.2519.
View the best growth stocks for 2024 here
.

When is FibroGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our FGEN earnings forecast
.

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) issued its earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.15. The biopharmaceutical company earned $27.14 million during the quarter, compared to analyst estimates of $40 million.

What other stocks do shareholders of FibroGen own?
When did FibroGen IPO?

FibroGen (FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.47%), Acadian Asset Management LLC (2.52%), Jacobs Levy Equity Management Inc. (2.22%), Assenagon Asset Management S.A. (0.43%), BNP Paribas Financial Markets (0.14%) and Public Employees Retirement System of Ohio (0.12%). Insiders that own company stock include Benjamin Cravatt, Christine Chung, Enrique A Conterno, James A Schoeneck, Jeffrey William Henderson, Juan Graham, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr.
View institutional ownership trends
.

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FGEN) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners